Metformin suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-+Leprdb/+Leprdb mice

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Ohno, Tomohiko ^a   Shimizu, Masahito ^a   Shirakami, Yohei ^a   Baba, Atsushi ^a   Kochi, Takahiro ^a   Kubota, Masaya ^a   Tsurumi, Hisashi ^a   Tanaka, Takuji ^a   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; DIETHYLNITROSAMINE; GLUCOSE; INSULIN; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PROTEIN KINASE B; S6 KINASE; ADIPOCYTOKINE; ANTIDIABETIC AGENT; MTOR PROTEIN, MOUSE; ONCOPROTEIN; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CONTROLLED STUDY; DB/DB MOUSE; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER ADENOMA; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MOUSE; NEWBORN; NONHUMAN; OBESITY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CARCINOGENESIS; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; LIVER; METABOLISM; TRANSGENIC MOUSE;

MAMMALIA; MUS;

ADIPOKINES; ANIMALS; ANIMALS, NEWBORN; CARCINOGENESIS; DIABETES MELLITUS, EXPERIMENTAL; DIETHYLNITROSAMINE; FEMALE; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIVER; LIVER NEOPLASMS; MALE; METFORMIN; MICE, INBRED C57BL; MICE, TRANSGENIC; OBESITY; ONCOGENE PROTEIN V-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84928473295     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124081     Document Type: Article

References (64)

1. The global challenge of diabetes. Lancet. 2008; 371:1723. doi: 10.1016/S0140-6736(08)60733-3 PMID: 18502275
2. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. The New England journal of medicine. 2003; 348:1625-38. PMID: 12711737
3. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371:569-78. doi: 10.1016/S0140-6736(08)60269-X PMID: 18280327
4. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2006; 4:369-80.
5. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010; 140:197-208. doi: 10.1016/j.cell.2009.12.052 PMID: 20141834
6. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011; 61:69-90. doi: 10.3322/caac.20107 PMID: 21296855
7. Imai K, Takai K, Nishigaki Y, Shimizu S, Naiki T, Hayashi H, et al. Insulin resistance raises the risk for recurrence of stage I hepatocellular carcinoma after curative radiofrequency ablation in hepatitis C virus-positive patients: A prospective, case series study. Hepatology research: the official journal of the Japan Society of Hepatology. 2010; 40:376-82. doi: 10.1111/j.1872-034X.2009.00616.x PMID: 20236359
8. Shimizu M, Kubota M, Tanaka T, Moriwaki H. Nutraceutical approach for preventing obesity-related colorectal and liver carcinogenesis. International journal of molecular sciences. 2012; 13:579-95. doi: 10.3390/ijms13010579 PMID: 22312273
9. Shimizu M, Tanaka T, Moriwaki H. Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis. Seminars in immunopathology. 2013; 35:191-202. doi: 10.1007/s00281-012-0336-6 PMID: 22945457
10. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nature reviews Cancer. 2012; 12:159-69. doi: 10.1038/nrc3215 PMID: 22337149
11. Hagiwara A, Nishiyama M, Ishizaki S. Branched-chain amino acids prevent insulin-induced hepatic tumor cell proliferation by inducing apoptosis through mTORC1 and mTORC2-dependent mechanisms. Journal of cellular physiology. 2012; 227:2097-105. doi: 10.1002/jcp.22941 PMID: 21769869
12. Kang S, Song J, Kang H, Kim S, Lee Y, Park D. Insulin can block apoptosis by decreasing oxidative stress via phosphatidylinositol 3-kinase- and extracellular signal-regulated protein kinase-dependent signaling pathways in HepG2 cells. European journal of endocrinology / European Federation of Endocrine Societies. 2003; 148:147-55. PMID: 12534368
13. Tornkvist A, Parpal S, Gustavsson J, Stralfors P. Inhibition of Raf-1 kinase expression abolishes insulin stimulation of DNA synthesis in H4IIE hepatoma cells. The Journal of biological chemistry. 1994; 269:13919-21. PMID: 8188671
14. Evert M, Calvisi DF, Evert K, De Murtas V, Gasparetti G, Mattu S, et al. V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis. Hepatology. 2012; 55:1473-84. doi: 10.1002/hep.25600 PMID: 22271091
15. Koketsu Y, Sakoda H, Fujishiro M, Kushiyama A, Fukushima Y, Ono H, et al. Hepatic overexpression of a dominant negative form of raptor enhances Akt phosphorylation and restores insulin sensitivity in K/KAy mice. American journal of physiology Endocrinology and metabolism. 2008; 294:E719-25. doi: 10.1152/ajpendo.00253.2007 PMID: 18270303
16. Calvisi DF, Wang C, Ho C, Ladu S, Lee SA, Mattu S, et al. Increased lipogenesis, induced by AKTmTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology. 2011; 140:1071-83. doi: 10.1053/j.gastro.2010.12.006 PMID: 21147110
17. Iwasa J, Shimizu M, Shiraki M, Shirakami Y, Sakai H, Terakura Y, et al. Dietary supplementation with branched-chain amino acids suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice. Cancer science. 2010; 101:460-7. doi: 10.1111/j.1349-7006.2009.01402.x PMID: 19906067
18. Kitade M, Yoshiji H, Kojima H, Ikenaka Y, Noguchi R, Kaji K, et al. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology. 2006; 44:983-91. PMID: 17006938
19. Sharma D, Wang J, Fu PP, Sharma S, Nagalingam A, Mells J, et al. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology. 2010; 52:1713-22. doi: 10.1002/hep.23892 PMID: 20941777
20. Shimizu M, Yasuda Y, Sakai H, Kubota M, Terakura D, Baba A, et al. Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-db/db obese mice. BMC cancer. 2011; 11:281. doi: 10.1186/1471-2407-11-281 PMID: 21711565
21. Stumvoll M, Haring HU, Matthaei S. Metformin. Endocrine research. 2007; 32:39-57. PMID: 18271504
22. Bhalla K, Hwang BJ, Dewi RE, Twaddel W, Goloubeva OG, Wong KK, et al. Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer prevention research. 2012; 5:544-52. doi: 10.1158/1940-6207.CAPR-11-0228 PMID: 22467080
23. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. The American journal of gastroenterology. 2013; 108:881-91. doi: 10.1038/ajg.2013.5 PMID: 23381014
24. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PloS one. 2012; 7:e33411. doi: 10.1371/journal.pone.0033411 PMID: 22448244
25. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005; 330:1304-5. PMID: 15849206
26. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. Journal of Clinical Investigation. 2001; 108:1167-74. PMID: 11602624
27. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer research. 2007; 67:10804-12. PMID: 18006825
28. Larsson O, Morita M, Topisirovic I, Alain T, Blouin MJ, Pollak M, et al. Distinct perturbation of the translatome by the antidiabetic drug metformin. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:8977-82. doi: 10.1073/pnas.1201689109 PMID: 22611195
29. Klein J, Westphal S, Kraus D, Meier B, Perwitz N, Ott V, et al. Metformin inhibits leptin secretion via a mitogen-activated protein kinase signalling pathway in brown adipocytes. The Journal of endocrinology. 2004; 183:299-307. PMID: 15531718
30. Asensio-Lopez MC, Lax A, Pascual-Figal DA, Valdes M, Sanchez-Mas J. Metformin protects against doxorubicin-induced cardiotoxicity: involvement of the adiponectin cardiac system. Free radical biology & medicine. 2011; 51:1861-71.
31. Chen HP, Shieh JJ, Chang CC, Chen TT, Lin JT, Wu MS, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut. 2013; 62:606-15. doi: 10.1136/gutjnl-2011-301708 PMID: 22773548
32. Cheng J, Huang T, Li Y, Guo Y, Zhu Y, Wang Q, et al. AMP-Activated Protein Kinase Suppresses the In Vitro and In Vivo Proliferation of Hepatocellular Carcinoma. PLoS One. 2014; 9:e93256. doi: 10.1371/journal.pone.0093256 PMID: 24709998
33. Cai X, Hu X, Cai B, Wang Q, Li Y, Tan X, et al. Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo. Oncol Rep. 2013; 30:2449-57. doi: 10.3892/or.2013.2718 PMID: 24008375
34. Saito T, Chiba T, Yuki K, Zen Y, Oshima M, Koide S, et al. Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells. PLoS One. 2013; 8:e70010. doi: 10.1371/journal.pone.0070010 PMID: 23922888
35. Toyama K, Nakamura T, Kataoka K, Yasuda O, Fukuda M, Tokutomi Y, et al. Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-gamma-dependent activity. Biochem Biophys Res Commun. 2011; 410:508-13. doi: 10.1016/j.bbrc.2011.06.012 PMID: 21679694
36. Tajima K, Nakamura A, Shirakawa J, Togashi Y, Orime K, Sato K, et al. Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice. American journal of physiology Endocrinology and metabolism. 2013; 305:E987-98. doi: 10.1152/ajpendo.00133.2013 PMID: 23964070
37. Popp JA, Goldsworthy TL. Defining foci of cellular alteration in short-term and medium-term rat liver tumor models. Toxicol Pathol. 1989; 17:561-8. PMID: 2697937
38. Frith CH, Ward JM, Turusov VS. Tumours of the liver. IARC scientific publications. 1994:223-69.
39. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41:1313-21. PMID: 15915461
40. Ohno T, Shirakami Y, Shimizu M, Kubota M, Sakai H, Yasuda Y, et al. Synergistic growth inhibition of human hepatocellular carcinoma cells by acyclic retinoid and GW4064, a farnesoid X receptor ligand. Cancer letters. 2012; 323:215-22. doi: 10.1016/j.canlet.2012.04.015 PMID: 22579649
41. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000; 85:2402-10. PMID: 10902785
42. Shimizu M, Sakai H, Shirakami Y, Iwasa J, Yasuda Y, Kubota M, et al. Acyclic retinoid inhibits diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BLKS/J-+(db)/+Lepr(db) mice. Cancer prevention research. 2011; 4:128-36. doi: 10.1158/1940-6207.CAPR-10-0163 PMID: 21071580
43. Shimizu M, Sakai H, Shirakami Y, Yasuda Y, Kubota M, Terakura D, et al. Preventive effects of (-)-epigallocatechin gallate on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db Mice. Cancer prevention research. 2011; 4:396-403. doi: 10.1158/1940-6207.CAPR-10-0331 PMID: 21372039
44. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007; 317:121-4. PMID: 17615358
45. Kawaguchi T, Izumi N, Charlton MR, Sata M. Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology. 2011; 54:1063-70. doi: 10.1002/hep.24412 PMID: 21563202
46. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, et al. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatology research: the official journal of the Japan Society of Hepatology. 2006; 35:204-14. PMID: 16737844
47. Kang JS, Wanibuchi H, Morimura K, Gonzalez FJ, Fukushima S. Role of CYP2E1 in diethylnitrosamine-induced hepatocarcinogenesis in vivo. Cancer Res. 2007; 67:11141-6. PMID: 18056438
48. Shirakami Y, Gottesman ME, Blaner WS. Diethylnitrosamine-induced hepatocarcinogenesis is suppressed in lecithin:retinol acyltransferase-deficient mice primarily through retinoid actions immediately after carcinogen administration. Carcinogenesis. 2012; 33:268-74. doi: 10.1093/carcin/bgr275 PMID: 22116467
49. Cua IH, Hui JM, Bandara P, Kench JG, Farrell GC, McCaughan GW, et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology. 2007; 46:66-73. PMID: 17596870
50. Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T, et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care. 1999; 22:818-22. PMID: 10332688
51. Sarafidis PA, Lasaridis AN, Nilsson PM, Pikilidou MI, Stafilas PC, Kanaki A, et al. Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes. J Hum Hypertens. 2007; 21:709-16. PMID: 17443211
52. Yokoyama H, Emoto M, Fujiwara S, Motoyama K, Morioka T, Komatsu M, et al. Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment in normal range weight and moderately obese type 2 diabetic patients. Diabetes Care. 2003; 26:2426-32. PMID: 12882874
53. Lee S, Muniyappa R, Yan X, Chen H, Yue LQ, Hong EG, et al. Comparison between surrogate indexes of insulin sensitivity and resistance and hyperinsulinemic euglycemic clamp estimates in mice. Am J Physiol Endocrinol Metab. 2008; 294:E261-70. PMID: 18003716
54. Minakawa M, Kawano A, Miura Y, Yagasaki K. Hypoglycemic effect of resveratrol in type 2 diabetic model db/db mice and its actions in cultured L6 myotubes and RIN-5F pancreatic beta-cells. J Clin Biochem Nutr. 2011; 48:237-44. doi: 10.3164/jcbn.10-119 PMID: 21562645
55. Minakawa M, Miura Y, Yagasaki K. Piceatannol, a resveratrol derivative, promotes glucose uptake through glucose transporter 4 translocation to plasma membrane in L6 myocytes and suppresses blood glucose levels in type 2 diabetic model db/db mice. Biochem Biophys Res Commun. 2012; 422:469-75. doi: 10.1016/j.bbrc.2012.05.017 PMID: 22579688
56. Cheong SH, Furuhashi K, Ito K, Nagaoka M, Yonezawa T, Miura Y, et al. Daidzein promotes glucose uptake through glucose transporter 4 translocation to plasma membrane in L6 myocytes and improves glucose homeostasis in Type 2 diabetic model mice. J Nutr Biochem. 2014; 25:136-43. doi: 10.1016/j.jnutbio.2013.09.012 PMID: 24445037
57. Eskens BJ, Zuurbier CJ, van Haare J, Vink H, van Teeffelen JW. Effects of two weeks of metformin treatment on whole-body glycocalyx barrier properties in db/db mice. Cardiovascular diabetology. 2013; 12:175. doi: 10.1186/1475-2840-12-175 PMID: 24308370
58. Bolukbas FF, Bolukbas C, Horoz M, Gumus M, Erdogan M, Zeyrek F, et al. Child-Pugh classification dependent alterations in serum leptin levels among cirrhotic patients: a case controlled study. BMC gastroenterology. 2004; 4:23. PMID: 15387890
59. Fujita H, Fujishima H, Koshimura J, Hosoba M, Yoshioka N, Shimotomai T, et al. Effects of antidiabetic treatment with metformin and insulin on serum and adipose tissue adiponectin levels in db/db mice. Endocrine journal. 2005; 52:427-33. PMID: 16127210
60. Villanueva EC, Myers MG Jr. Leptin receptor signaling and the regulation of mammalian physiology. Int J Obes (Lond). 2008; 32 Suppl 7:S8-12.
61. Akasaka Y, Tsunoda M, Ogata T, Ide T, Murakami K. Direct evidence for leptin-induced lipid oxidation independent of long-form leptin receptor. Biochim Biophys Acta. 2010; 1801:1115-22. doi: 10.1016/j.bbalip.2010.06.009 PMID: 20601111
62. Liu ZJ, Bian J, Liu J, Endoh A. Obesity reduced the gene expressions of leptin receptors in hypothalamus and liver. Horm Metab Res. 2007; 39:489-94. PMID: 17611900
63. Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, Green RM, et al. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. American journal of physiology Gastrointestinal and liver physiology. 2004; 287: G1035-43. PMID: 15256362
64. Yang S, Lin HZ, Hwang J, Chacko VP, Diehl AM. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition? Cancer research. 2001; 61:5016-23. PMID: 11431335